Sun Pharmaceutical Industries has declared a strong financial performance for the third quarter of the year. Its pharmaceutical powerhouse announced a growth of both its top and bottom lines in the two-digit growth, which demonstrates its strong operational results. The consolidated net profit of the company increased by 16% per annum to ₹3,369 crore in the quarter. This is a significant jump compared to the ₹2,903 crore that was registered in the same period of the last financial year. These figures, which were announced in the exchange filing of the company on Saturday, show a gradual upward trend in the profitability of the firm.
Strong operation and quarterly performance
Besides increasing the net profit, Sun Pharma experienced significant growth in its consolidated revenue from operations. The figure increased by 13.5% to ₹15,520 crore, as opposed to ₹13,675 crore in the previous year.
The operational leverage of the company was also high since its EBITDA increased by 23.4% to ₹4,948 crore as compared to ₹4,009 crore of the same quarter the previous year. This performance resulted in a major increase in EBITDA margins that shifted the margin from 29.3% to 31.9% per year. This type of margin expansion implies that the company could control its costs and increase the scope of its business operations.
After the impressive performance of 1st quarter, the board of Sun Pharma has announced a transient dividend of ₹11 per equity share of Re 1 each in terms of the financial year 2025-26. This dividend is a reward to the stockholders in the profitable expansion of the firm.
To enable this, the company has set the record date as February 05, 2026, in establishing the eligibility of the shareholders to receive the dividend. The dividend would be paid to the holding shareholders on or before 16 February 2026, according to the announcement made by the company.
Performance and segment growth
The company also enhanced its performance through its India formulations business that has registered sales of ₹4,998.6 crore, which is a growth of 16.2%. The company has a crucial part of its portfolio in the domestic market with an estimated 32.3% of the total consolidated sales.
In the US, the biggest pharmaceutical market, formulation sales increased slightly by 0.6% to $477 million. The company has reported that the growth in its Innovative Medicines line served as a critical factor in counteracting the shrinkage realised in its generics line of business in the US market.
The Managing Director of Sun Pharma, Kirti Ganorkar, was pleased with the quarterly results, and she stated that it demonstrates overall balanced growth of the business in different segments. He particularly identified the leadership of the Branded businesses in India, Emerging Markets, and the Global Innovative Medicines segment as the main contributors to this success.
Ganorkar focused on the growth of innovative products of the company, referring to the introduction of Unloxcyt to the US market and Ilumya to India. These measures will provide differentiated therapies and significant innovation to patients around the world.
Conclusion
The third quarter of the 2025-26 fiscal year performance of Sun Pharmaceutical Industries highlights its strong market performance and operational capacity. By using its innovative medicine portfolio, the company has successfully overcome the competition in the market, especially in the US generics, as its net profit has increased by 16% and its revenues by double digits.
The announcement of a ₹11 dividend shows that the management is optimistic about the financial position of the company. As Sun Pharma keeps launching new treatments and entering more markets in the domestic and international markets, it is a giant in the pharmaceutical industry globally.
Read the full article here